spacer
home > ebr > spring 2017 > express yourself
PUBLICATIONS
European Biopharmaceutical Review

Express Yourself

EBR: Oxford Genetics offers numerous services in preclinical R&D. Can you tell us a little about some of these?

Paul Brooks: Oxford Genetics is a synthetic biology company that offers products and services to support the discovery, development and production of biologics, gene and cell therapies. We have tremendous expertise in designing DNA, optimising expression of proteins, improving viral delivery systems and cell line development.

In your opinion, what is the significance of the research undertaken at Oxford Genetics for the wider patient base, and how does it contribute to the production of new and efficacious vaccines?

Oxford Genetics is addressing some of the fundamental problems affecting the biopharmaceutical industry in relation to maximising productivity. We are helping to achieve cost-effective production of material for clinical testing and commercial manufacture from smaller batch sizes, which offers a viable route to market for therapies that might not otherwise make it.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Ryan Cawood is Chief Executive Officer and founder of Oxford Genetics. He established the company in 2011 with the aim to revolutionise DNA design, optimisation and assembly in order to enable molecular engineering to fulfil its promise in synthetic biology and medicine. Ryan’s research interests include vaccines and treatments for infectious diseases and cancer. He was inspired to create Oxford Genetics after observing that inefficient DNA design and assembly often limit scientific progress. Ryan has a degree in Genetics and a PhD from Oxford University, UK.

Paul Brooks is Commercial Director at Oxford Genetics. He recently joined the company from Sigma-Aldrich, where he was responsible for the commercialisation of their functional genomic technologies – including those for genome-editing. Over the course of his career, Paul has held various senior management positions in both the US and Europe, and has overseen the development, marketing and sales of genomic technologies, products and services. He holds a PhD in Molecular Biology from the University of Manchester, UK, and an MBA from the University of Nottingham, UK.
spacer
Ryan Cawood
spacer
spacer
spacer
Paul Brooks
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Significant expansion in Serialization technology, tripling global capacity

PCI Pharma Services (PCI) today announced a significant expansion of its market leading Serialization capability. PCI will increase Serialization capacity across its global supply network to support clients in advance of meeting both US DSCSA and EU FMD implementation dates. PCI has partnered with Antares Vision, Marchesini and Domino for this latest installation, utilizing Antares’ leading Serialization platform and technology architecture across a variety of Serialization technology platforms and applications
More info >>

White Papers

Sourcing Commercial Drugs for Clinical Trials: US vs. EU Understanding the Differences

Myoderm

Sourcing commercial drugs for clinical trials is a dynamic process. There are many factors to consider: single source or regional sourcing, strategy, price, supply availability, lead times, and documentation are just a few. In the past, there were fewer clinical trials that required commercial drug sourcing, so demand was not as high. Today, the demand for commercial drugs in clinical trials has greatly increased and, as a result, inventory is tighter, orders are monitored more closely by manufacturers, and lead times have increased. This report highlights the key differences in sourcing from the US and EU.
More info >>

 
Industry Events

Clinical Trial Supply West Coast conference 2017

24-25 May 2017, Burlingame, California

Clinical Trial Supply West Coast returns in 2017 this time in Burlingame. Attracting the leading biotech and pharma companies from Northern California and beyond, the event will focus on how drug companies can adapt their supply chains to fit into the highly regulated world. For the first time key topics will be explored through Debates, Workshops and extended Roundtable discussions. With standout presenters from Sanofi, Genentech, Dynavax and Gilead, this is an event not to miss out on – reserve your place today!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement